Navigation Links
Chimerix to Present at Upcoming Lazard and Piper Jaffray Healthcare Conferences
Date:11/9/2011

e 2 clinical development for the prophylaxis of cytomegalovirus (CMV) and the preemption and treatment of adenovirus infection in hematopoietic cell transplant recipients. Data from an ongoing, placebo-controlled Phase 2 CMV prophylaxis trial is expected during the first quarter of 2012.  In an emergency IND cohort of adenovirus-infected transplant recipients, CMX001 has demonstrated its ability to reduce viremia and improve survival.  To date, more than 650 patients have been dosed with CMX001 in placebo-controlled clinical trials and open-label treatment protocols.

CMX001 is also being developed as a medical countermeasure in the event of a smallpox release, with the potential to provide an important therapeutic option for the 80 million people in the U.S. currently estimated to be immunocompromised and thus not candidates to receive a smallpox vaccine.  Chimerix has received federal funding for the development of CMX001 as a medical countermeasure against smallpox from the National Institute of Allergy and Infectious Diseases under Grant No. U01-A1057233 and from the Biomedical Advanced Research and Development Authority (BARDA), Office of the Assistant Secretary for Preparedness and Response, Office of the Secretary, Department of Health and Human Services, under Contract No. HHSO100201100013C.  

Chimerix's second clinical-stage antiviral compound, CMX157, is a lipid-antiviral-conjugate that delivers high intracellular levels of the active antiviral agent tenofovir-diphosphate.  CMX157 is in development as a potent nucleoside analogue against HIV and HBV infections, and has the potential to directly address several limitations of current therapies.  CMX157 has completed a Phase 1 clinical trial in healthy volunteers, providing pharmacokinetic data which support the compound's enhanced characteristics.  

Led by an experienced antiviral drug development team, Chimerix is also leveraging its lipid conjugate t
'/>"/>

SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Chimerix Honored With "2011 Southeast BIO Deal of the Year: Venture Capital Transaction" Award
2. Chimerix Announces Late-Breaker Presentation at 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Annual Meeting
3. Chimerix to Present at Infocasts 9th Annual Biodefense Vaccines & Therapeutics Conference
4. Chimerix Appoints Timothy W. Trost Senior Vice President, Chief Financial Officer
5. Chimerix to Present at Cowen and Company 31st Annual Health Care Conference
6. Disseminated Adenovirus Infection Eradicated in a Pediatric Hematopoietic Stem Cell Transplantation Recipient Who Received Chimerixs Lead Antiviral CMX001
7. Chimerix to Present at the Citi 2011 Global Health Care Conference
8. Chimerix Commences CMX001 Open-Label Clinical Study for the Treatment of Patients With Life-Threatening or Serious dsDNA Viral Infections
9. Chimerixs Antiviral CMX157 Demonstrates Positive Phase 1 Clinical Results With Favorable Pharmacokinetics, Safety and Tolerability
10. Chimerix to Present at the Lazard Capital Markets 7th Annual Healthcare Conference
11. Chimerix Reaffirms Its Commitment to CMX001 as a Medical Countermeasure for Smallpox and Broad-Spectrum Antiviral Agent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... LONDON , August 28, 2015 ... seamlessly connects people, technologies and care protoc ... improving outcomes and the cost of healthcare delivery   ... today announced its presence at  ESC Congress 2015 , where the ... A.I. , EchoNavigator and IntelliSpace Cardiovascular, that connect people and ...
(Date:8/27/2015)...  A recent study by Feucht et al, ... Arthrosurface HemiCAP® Wave implant, which is based on ... implant for isolated patellofemoral disease. While both implant ... scores, none of the patients in the "inlay" ... of the patients in the "onlay" group, showed ...
(Date:8/27/2015)... , Aug. 27, 2015 ieCrowd™ ... in the commercial development of the company,s supplemental ... Smart Oxygen device, being developed by ieCrowd,s subsidiary ... a patient,s changing demand for oxygen based on ... 510 (k) submission for the Smart Oxygen device ...
Breaking Medicine Technology:Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 2Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 3Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 4Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 2Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 3Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone 2Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone 3Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone 4
... the global leader in technology support and BPO services ... today the opening of its new Global Operations Center ... city of Dalian, will specialize in providing services in ... sponsors and clinical research organizations. With dramatic ...
... ARBOR, Mich., April 7, 2011 Adeona Pharmaceuticals, Inc. (AMEX: ... serious central nervous system diseases, announced today that it has ... its common stock at approximately $2.0725 per share to a ... million in gross proceeds. The investor will also receive warrants ...
Cached Medicine Technology:C3i Opens Asia Language Center in Dalian, China 2Adeona to Raise $3.5 Million in Registered Direct Offering 2Adeona to Raise $3.5 Million in Registered Direct Offering 3
(Date:8/29/2015)... ... August 29, 2015 , ... Vascular ... market and sell Arterosil and Arterosil HP, and that all claims and counterclaims ... Vascular Health Sciences, LLC (VHS) in the United States District Court for the ...
(Date:8/28/2015)... ... 2015 , ... The Kentucky State Department of Workforce Investment Commissioner Beth Kuhn ... applying for, they are unable to pass the initial drug test and therefore unable ... in order to be able to hire long-term, skilled talent. (1) Will Wesch, Director ...
(Date:8/28/2015)... ... , ... As reported by Medical Daily on August 22 , Cellfina, ... last for two years, the longest of any cellulite reduction system currently on the ... long-lasting, effective solution for their cellulite, according to Dr. Robert Weiss, director of the ...
(Date:8/28/2015)... ... , ... “ Frequentz ” was featured on NewsWatch as part of its ... market for iOS, Android, and Windows. Joe Toohey, the host of AppWatch and technology ... to track product movement from beginning to end. , Businesses benefit greatly from having ...
(Date:8/28/2015)... , ... August 28, 2015 , ... ... three-year accreditation for its adolescent residential, counseling, day treatment and intensive family based ... meets international standards for quality and its pursuit of excellence. As a nonprofit ...
Breaking Medicine News(10 mins):Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 2Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 3Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 4Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 3Health News:Track Product Movement from Beginning to End with Frequentz 2Health News:West Ridge Academy Awarded CARF Three-Year Accrediation 2
... diet/nutrition as leading issue; exercise, physical changes, ... drug use also rank ... report from,the C.S. Mott Children,s Hospital National Poll on Children,s Health ... with kids ages 11 to 17 during routine check-ups. The topics ...
... Davis Collaboration, RANCHO CORDOVA, Calif., Feb. 6 ... supplier of innovative products and,services that process and ... injury, today announced a regenerative medicine initiative in ... wholly-owned subsidiary, Vantus, Inc., a,veterinary stem cell laboratory ...
... first step toward personalized medicine, experts say , , WEDNESDAY, Feb. ... blood test could help a small minority of HIV patients ... can sometimes cause serious side effects. , The test detects ... a patient,s genetic makeup is linked to poor reactions to ...
... multiple risk factors at once, , , WEDNESDAY, Feb. 6 (HealthDay ... showing signs of some kidney damage may be able to ... factors at once. , That,s the conclusion of a ... the New England Journal of Medicine , that found ...
... Burnham Institute for Medical Research (Burnham Institute) have provided ... a suppressor role in skin cancer development. ATF2 ... the first step in the translation of genetic code, ... and ionizing radiation. This function of ATF2 in ...
... has announced the names of the recipients of its annual ... Inder Verma is the prize recipient for biomedical science; the ... The Vilcek Foundation Prizes are awarded annually to foreign-born individuals ... , In explaining the motivation for the awards, Dr. ...
Cached Medicine News:Health News:Parents Identify Health Topics They Want Doctors to Discuss with Kids - New Research for University of Michigan Conducted by Knowledge Networks 2Health News:Thermogenesis Announces New Initiative to Address Veterinary Regenerative Medicine 2Health News:Thermogenesis Announces New Initiative to Address Veterinary Regenerative Medicine 3Health News:Thermogenesis Announces New Initiative to Address Veterinary Regenerative Medicine 4Health News:Test Detects Sensitivity to HIV Drug 2Health News:Aggressive Diabetes Therapy Lowers Death Risk, Study Finds 2Health News:Aggressive Diabetes Therapy Lowers Death Risk, Study Finds 3Health News:Gene found to play a suppressor role in skin cancer development 2Health News:Dr. Inder Verma named recipient of 2008 Vilcek Prize in biomedical science 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: